Agenda April, 2026

Patient Assessment
Elliot Dinetz, M.D., ABFM, FAAMFM
Medical Director, Timeless Health, Miami, FL
Member, AMMG Conference Planning Committee

Presented by James Powell, R.N.

Open to all attendees and includes a complimentary lunch

Non-CME Symposium Sponsored by Doc Loop

Open to all conference attendees, spouses and guests

Held in Conference Networking and Exhibits Center

Nutraceuticals, which encompass dietary supplements, functional foods, and herbal products, play a critical role in preventive and longevity medicine. As interest in holistic health grows, these compounds are recognized for their potential to enhance well-being, prevent chronic diseases, and promote healthy aging. Nutraceuticals can provide essential nutrients that may be lacking in conventional diets, thereby supporting optimal physiological functions. Research has shown that certain nutraceuticals, such as omega-3 fatty acids, antioxidants, and polyphenols, can mitigate inflammation, improve cognitive function, and reduce the risk of age-related diseases like cardiovascular issues and diabetes. By targeting the underlying mechanisms of aging, such as oxidative stress and cellular degradation, nutraceuticals can help maintain homeostasis and support overall health. Moreover, the integration of nutraceuticals into preventive medicine is associated with other lifestyle modifications, such as balanced diets and regular physical activity, creating a synergistic effect on health outcomes. Health professionals increasingly advocate for personalized approaches, recognizing that individual responses to nutraceuticals may vary based on genetics, lifestyle, and existing health conditions. In summary, nutraceuticals represent a promising avenue for enhancing longevity and preventing disease, positioning them as essential components in modern preventive healthcare strategies.

The conventional focus on body weight as the primary metric of obesity treatment is clinically obsolete. This lecture reframes the conversation around what truly matters: body composition — the ratio of fat mass to lean mass, and specifically the burden of visceral adipose tissue that drives insulin resistance, systemic inflammation, and cardiometabolic disease. Attendees will explore the latest science in precision fat loss, including optimal methods of body composition assessment (DEXA vs. BMI), the metabolic superiority of targeting visceral fat, and the critical role of skeletal muscle as an endocrine organ. Evidence-based exercise prescriptions — resistance training, HIIT, and VO₂ Max-guided training zones — will be reviewed alongside protein requirements for muscle preservation during fat loss. The lecture examines the common denominator across all successful dietary interventions, compares popular diets by clinical evidence, and introduces nutrigenomic testing (GXSlim) for personalized diet and exercise prescriptions. Current and emerging pharmacotherapy — including GLP-1 receptor agonists, the historical development of FDA-approved obesity medications, non-FDA peptides (AOD-9604, MOTS-C), and hormone optimization for both men and women — are addressed with clinical depth. Special attention is given to the impact of sleep on fat loss hormones, chronic disease conditions where fat loss is transformative, and clinical scenarios — including sarcopenia and osteopenia — where aggressive weight loss can be harmful.

Coronary Artery Disease is one of the leading causes of death in the US. Currently, using AI we can accurately assess the FFRCT for Coronary obstruction as well as Plaque analysis. The vast majority of heart attacks occur because of the instability of plaques, and NOT because of the degree of obstruction in the arteries. This lecture will show how we can now evaluate both of these in an accurate and non invasive manner. The audience will learn how to use these modalities in their everyday practice.

Presented by James Powell, R.N.

Open to all attendees and includes a complimentary lunch

Non-CME Symposium Sponsored by Doc Loop

Testosterone levels decline with age in men and are associated with changes in body composition, bone density, muscle strength, metabolic health, sexual health and cognition.This lecture will review the physiology of age -related decline, distinguishes normal aging from hypogonadism and summarizes current evidence of the benefits and risks of testosterone replacement.

This lecture explores how applied genomics can serve as the clinical operating system for longevity, enabling clinicians to move beyond symptom-based care toward proactive, pathway-driven strategies that optimize health span and resilience. Through a practical framework and real-world cardiovascular and cognitive case examples, Dr. Lile demonstrates how integrating genomic data with biomarkers and clinical history can uncover hidden risk, refine prevention strategies, and guide precision interventions. The session emphasizes translating complex genomic insights into actionable clinical decisions that support long-term health and disease prevention.

Peptides are a rapidly growing topic in health and performance medicine and have gained widespread popularity, including among college-aged individuals. The human body produces nearly 300,000 peptides, yet only a small fraction is well understood and clinically utilized. In this lecture, we will focus on five peptides with strong clinical relevance in wellness and longevity medicine. These peptides have demonstrated benefits in:
– Mitochondrial function and cellular energy
– Immune modulation
– Tissue recovery and repair
– Cognition
– Strength, body composition, and skin health
Each peptide is unique in its mechanism of action, and three of the five are naturally produced by the human body. Clinical indications, safety considerations, and practical usage protocols will be reviewed.

Open to all conference attendees, spouses and guests

Held in Conference Networking and Exhibits Center

Lipopolysaccharide (LPS, endotoxin), the gram negative bacteria’s armored vest, is the most potent environmental inflammatory trigger known to science. It’s end-stage crisis sepsis, is the leading cause of death in U.S. hospitals (270,000 Americans per year), and the number one cost of hospitalization in the U.S. at an estimated $62 billion annually. But sepsis is just the end-stage visible tip of the endotoxin iceberg. Low-grade LPS infiltration can begin in utero and silently drive a reduction in utero neurogenesis, reduced myelination of the vagus nerve, fetal disruption of the blood brain barrier and life-long consequences.
– Key Takeaway: The revelation in this introductory session is that ‘What Kills in Hospitals Circulates Chronically for years in Primary Care Offices’. This interactive seminar will focus on an update of this primary determinant of disease development, but also one that is very modifiable or manageable in the majority of patients.

Purpose: Build foundational understanding of endotoxin as a primary inflammatory driver.  And how it develops.
Core Topics:
– Intestinal permeability vs. microbial translocation
– Zonulin, tight junction injury, and epithelial stress
– When LPD Translocation occurs without classic “ leaky gut”
– Alveolar-capillary permeability “leaky lungs”
– Blood Brain Barrier permeability “leaky brain”
– Blood Testes Barrier permeability “leaky testes”
– Tissue deposition: lymphatics liver, vasculature, brain
– Hidden sources of LPS intake
– Why LPS is not easily cleared once deposited
– Key Takeaway:  Endotoxin accumulation creates self-perpetuating inflammatory loop

Lecture Description TBA

Presented by James Powell, R.N.

Open to all attendees and includes a complimentary lunch

Non-CME Symposium Sponsored by Doc Loop

Open to all conference attendees, spouses and guests

Held in Conference Networking and Exhibits Center

For decades, traditional pharmacotherapy has been sold as the engine of better health and longer life. Yet when stripped of the marketing rhetoric and relative risk spin, the evidence tells a far less inspiring story: most widely prescribed medications do almost nothing to extend human lifespan. Statins, antihypertensives, antiplatelets, glucose-lowering agents, and countless other “preventive” drugs deliver striking improvements only on paper—dramatic relative risk reductions that mask microscopic absolute gains. For most patients, especially those without severe disease, these interventions add little more than days to months of life, often at the cost of side effects, polypharmacy, and medicalization of the otherwise healthy. Traditional pharmacotherapy excels at altering laboratory numbers yet fails to meaningfully modify the fundamental biology aspects of aging: mitochondrial dysfunction, metabolic rigidity, hormonal decline, and loss of cellular resilience among others. Meanwhile, interventions grounded in physiology—lifestyle optimization, hormonal restoration, regenerative therapies, metabolic optimization—show a far greater potential to shift the trajectory of aging than any pill designed to tweak a surrogate marker. The belief that more pharmaceuticals equal more life is not only scientifically unsubstantiated, it is one of the most persistent illusions in modern medicine. A paradigm shift, which is overdue, will be presented in this lecture.

The underlying cause of chronic disease and aging is metabolic dysfunction. At the cellular level, this is ultimately caused by dysregulation of the epigenetic control of key metabolic pathways.  AMPK, the master regulator of metabolism, ultimately regulates these pathways. Any inhibition of AMPK activity will manifest itself in earlier development of chronic disease conditions associated with insulin resistance and the acceleration of cellular senescence. Metabolic Engineering is an integrated dietary program composed of a highly defined calorie restriction program coupled with adequate omega-3 fatty acid and polyphenol supplementation to activate AMPK and maintain it within a therapeutic zone necessary to epigenetically reprogram a disrupted metabolism.  Published clinical data will be discussed.

Dr. Maureen Pickle, DMSc, MPH, PA-C, will present Practical Applications for Supporting Immune Health, offering dynamic insight into the multilayered immune defense network. Dr. Pickle will cover the latest advancements in immune health, focusing on the gut-lung axis and the role of probiotics and more specifically immunobiotics in enhancing immune function. Key topics include the impact of respiratory and digestive microbiomes on overall health, the benefits of specific probiotic strains like LGG® and BB-12®, and fermentation products designed for daily immune support. The presentation also highlights clinical studies demonstrating the effectiveness of immunobiotics in supporting respiratory comfort and boosting immune responses. This comprehensive overview aims to provide practical insights for healthcare professionals to support immune health in their patients.

Presented by Joshua Johnson, Educator

Open to all attendees and includes a complimentary lunch

Non-CME Symposium Sponsored by Fortune Law Firm

This practical, high-impact lecture expands on the foundational science of endotoxin (lipopolysaccharides, LPS) and focuses on clinical application: how to assess, intervene, and restore resilience in patients whose healthspan is silently eroding under the weight of chronic LPS driven inflammation.  We begin with comprehensive strategies to identify the magnitude and scope of LPS burden—not just in the gut, but where it matters most: the brain. Although the brain represents only 2% of total body mass, it carries up to 18% of total blood flow at any one time, and is one of the earliest sites to reflect immune-mediated damage. Biomarkers of neuroinflammation, blood–brain barrier permeability, and immune overactivation will be explored, with clear guidance on when and how to use them.  From there, we will explore multi-phased, integrative protocols to:

• Disrupt and disarm microbial biofilms
• Enhance glymphatic and lymphatic detoxification
• Support liver and microbiome crosstalk
• Calm the neuroimmune axis and restore immune tolerance
• Reduce cognitive risk and systemic vulnerability to sepsis

This is more than an academic review.  It is a call to clinical action providing participants with the lab, interpretation tools, and layered therapeutic frameworks to implement Monday morning.

Metabolic dysfunction develops years before emerging symptoms of disease. Precision diagnostics, including metabolomic profiling, advanced lipid panels, and genomic insights, enable us to detect biological abnormalities throughout all decades of life typically overlooked with standard conventional studies. These cases demonstrate how technology and wearables are reshaping our understanding of metabolic health in an era where patients think they are doing all the right things, and yet are still sick under the surface.

Is there a pill that can make you biologically younger? As longevity science advances, much attention has focused on senescent cells, cell cycle arrest, and the role of the senescence-associated secretory phenotype (SASP) in aging. Rapamycin has demonstrated lifespan extension in rodents and other species, leading to widespread off-label use in wellness settings, and emerging data on its effects on biological age will be reviewed; however, because SASP also contributes to anti-inflammatory signaling, tissue repair, regeneration, and tumor suppression, suppressing it in healthy individuals may not be beneficial and could potentially accelerate aspects of aging. Similarly, Fisetin—along with other senolytics such as dasatinib and quercetin—has shown promise in animal studies, yet human data, particularly in healthy cohorts, have not replicated those results, with one study showing an increase in biological age in 50% of participants. These findings suggest that while senolytics and mTOR modulation may have therapeutic roles in individuals with significant senescent cell burden or age-related disease, they are not one-size-fits-all interventions and may pose risks when used indiscriminately in otherwise healthy populations.

Therapeutic plasma exchange (TPE) is a blood purification technique which functions to remove pathological plasma constituents such as autoantibodies, inflammatory cytokines, immune complexes, and extracellular vesicles that contribute to a range of disease states. TPE has been available to the medical community for over 50 years. This exciting seminar will review the contemporary literature concerning this most timely subject related to toxin removal and heart disease, oncological diseases, inflammatory disorders, autoimmune processes, and other metabolic dysfunctions.

Open to all conference attendees, spouses and guests

Held in Conference Networking and Exhibits Center

This interactive seminar will focus on endocrine disrupting chemicals, in particular Bisphenol A (BPA). BPA can disrupt the function and activity of the body’s own hormones which cause dysfunction in the hypothalamus-pituitary-gonadal glands as well as the pituitary-adrenal function. BPA has been found in the urine of 93% of people in the United States. It can also damage the immune system, neuroendocrine system, cardiovascular system, and other parts of the body. Exciting new therapies for BPA removal will be examined in this thought-provoking seminar. Serial Therapeutic Plasma Exchange: The End of Toxicity a Contemporary Literature Review AbstractTherapeutic plasma exchange (TPE) is a blood purification technique which functions to remove pathological plasma constituents such as autoantibodies, inflammatory cytokines, immune complexes, and extracellular vesicles that contribute to a range of disease states. TPE has been available to the medical community for over 50 years. This exciting seminar will review the contemporary literature concerning this most timely subject related to toxin removal and heart disease, oncological diseases, inflammatory disorders, autoimmune processes, and other metabolic dysfunctions.

Sarcopenia, the age-related loss of muscle mass and strength, poses significant health challenges, particularly for older adults. With the increasing popularity of GLP-1 (Glucagon-Like Peptide-1) receptor agonists for managing obesity and type 2 diabetes, concerns about potential side effects, including accelerated muscle loss, have emerged. While GLP-1 medications can effectively promote weight loss and improve metabolic health, they may inadvertently contribute to sarcopenia by reducing caloric intake and altering nutrient absorption. Preventing sarcopenia in individuals using GLP-1 therapies requires a proactive approach that emphasizes proper nutrition and physical activity. Firstly, ensuring adequate protein intake is crucial; protein serves as the building block for muscle tissue, and older adults often need more than the standard dietary recommendations. Incorporating strength training exercises is equally essential, as resistance training stimulates muscle growth and preserves strength. Regularly engaging in such activities can counteract the muscle-depleting effects of weight loss and enhance overall physical function. Ultimately, a comprehensive strategy that combines a high-protein diet with structured exercise can mitigate the risks of sarcopenia for those on GLP-1 medications, promoting a healthier and more active lifestyle well into older age.

The Laboratory of Functional Medicine—Part 2 advances our fall 2025  Part-1 framework from “what to order” toward “how to read what matters.” We work beyond population ranges to physiologic medians, integrating multi-matrix data to make our labs a living clinical map. From a hormone-centric perspective, we start with salivary and urinary hormone interpretations: saliva for diurnal rhythm and stress adaptation; urine for metabolism, conjugation pathways, and treatment response. When combined, this data clarifies the hormonal landscape. For example, is our patient’s fatigue adrenal, thyroid, circadian, or simply mis-timed dosing?  We then provide practical guidelines for selecting the appropriate matrix for each hormone. Next, we explore immune and environmental signals. Delayed IgG food sensitivities are framed through gut–immune crosstalk associated with symptom clusters. We explore the toxic burdens—heavy metals, molds and mycotoxins, and broader environmental exposures that are linked to mitochondrial throughput, neurocognitive drag, endocrine disruption, and cardiometabolic risk. We proceed step-wise, real-world algorithms for staging assessment, sequencing detoxification, and monitoring. Lastly, we demystify micronutrient testing, prioritizing intracellular and functional proxies that explain “normal labs, abnormal symptomatology.” Our goal is to present a scalable, precision-first laboratory strategy—pragmatic and immediately usable—that anticipates disease, accelerates recovery, and personalizes care for complex endocrine, inflammatory, and environmental conditions.

Population-based laboratory reference ranges have long served as the foundation for clinical decision-making, yet their statistical origins limit their ability to reflect optimal physiological function. Derived from heterogeneous populations and designed primarily to identify overt disease, these ranges frequently fail to detect early biochemical insufficiency, states in which laboratory values remain “normal” while cellular, neuroendocrine, and metabolic function decline. This presentation examines the conceptual and clinical shortcomings of population-derived reference intervals and proposes an outcome-based, precision physiology framework for laboratory interpretation.Using endocrine and neuroendocrine biomarkers, particularly free testosterone, as illustrative examples, we demonstrate how values within the lower quartiles of accepted reference ranges are often insufficient to support optimal androgen receptor activation, mitochondrial energy production, neurosteroid synthesis, and cognitive-emotional resilience. These insufficiency states frequently manifest as fatigue, mood disturbance, cognitive impairment, metabolic instability, and diminished quality of life, yet remain unaddressed under traditional interpretive models. We introduce outcome-based reference modeling as an alternative approach, emphasizing longitudinal biomarker trends, multi-system integration, individualized baselines, and correlation with patient-reported outcomes. Systems-based tools, including multi-cluster biomarker panels and AI-driven clinical decision support platforms, enable earlier identification of functional decline and facilitate personalized intervention before irreversible pathology develops. By reframing laboratory values as dynamic signals rather than static thresholds, this model shifts medicine from reactive disease detection toward predictive, preventive, and regenerative care. The presentation concludes by redefining “normal” as a functional bandwidth associated with measurable improvements in energy, cognition, emotional stability, and metabolic health, thereby aligning laboratory medicine with the principles of precision physiology and individualized human performance optimization.

Presented by Lana Graff, Lead Clinical Specialist

Open to all attendees and includes a complimentary lunch

Non-CME Symposium Sponsored by Elitera Aesthetics

Inflammatory Bowel Diseases are a group of conditions that cause long-term inflammation of the gastrointestinal tract. Symptoms are sometimes vague and patients get misdiagnosed as having other conditions.  This evidence-based presentation with refences reviews the latest studies on the causes, best diagnostics, and most effective treatments for Inflammatory Bowel Diseases.

Brand new research inside the hyperbaric industry has been released. This research will alter the course of hyperbarics as well as the use of this equipment in the regenerative and longevity medicine industry forever. Be one of the first practitioners to see the results and learn how using this technology inside your clinic can improve patient outcomes.

This paper will once more recap the benefits of reducing senescent cell load in Asian Americans but will address the latest research in finding less toxic and hopefully equally efficient methods for reducing senescent cell burden. It will address the literature on the dasatinib quercetin studies as well as the newer studies involving Fisetin. The evolving literature is showing that Fisetin in high doses using an intermittent pattern similar to what we had used with D/Q, is reasonably effective without the toxicity sometimes encountered with the D/Q combination. I will recap the experience we have had in our clinic with hundreds of D/Q patients over the past 3 years and compare it with what we are encountering with the alternative program.

With the FDA removal of the Black box warning from hormone therapy for woman, providers who have been hesitant to prescribe are offering hrt liberally. They do not know what they do not know.  Dosing, delivery method and metabolism have never been taught or spoken of for 20years in traditional GYN. The physiologic changes in early perimenopause verses late perimenopause and menopause are poorly understood.  The impact of menopause on the adrenal function and thyroid is also rarely discussed.  Let’s explore the intricate details and elucidate their importance on the health and longevity in women.

Emerging evidence identifies beta-alanine as a key nutritional precursor for carnosine synthesis, a dipeptide essential for maintaining cellular homeostasis in both muscle and neural tissues. Carnosine’s buffering, antioxidant, and antiglycation properties have been shown to support muscle endurance, mitigate sarcopenic decline, and promote cognitive resilience during aging. Sustained-release and high-bioavailability forms of beta-alanine enable efficient dosing without paresthesia and demonstrate safety and stability suitable for daily clinical use. This presentation will review the latest human data on muscle and brain outcomes and highlight mechanistic insights Practical clinical integration strategies and dosing considerations for aging and wellness populations will also be discussed.

Chronic low-grade systemic inflammation, commonly referred to as inflammaging, is a central biological process linking aging to cardiometabolic disease, autoimmunity, infection severity, and mortality. Despite its clinical importance, inflammaging is not well captured by conventional inflammatory markers, which primarily reflect acute or late-stage processes. IgG glycosylation has emerged as a biologically grounded and dynamic marker of chronic immune activation, reflecting the cumulative influence of genetic, metabolic, hormonal, and environmental factors on immune function years before overt disease becomes clinically apparent. Glycans attached to the Fc region of immunoglobulin G directly modulate antibody effector function, thereby influencing immune activation and resolution. Specific patterns of IgG glycosylation have been consistently associated with biological aging and with risk across a broad range of conditions, including cardiovascular and metabolic disease, autoimmune disorders, neurodegeneration, and cancer. Importantly, these glycan patterns often change well in advance of clinical diagnosis, suggesting potential utility in earlier risk stratification. From a clinical perspective, IgG glycosylation is not static. Longitudinal and interventional studies demonstrate that IgG glycan profiles respond to interventions commonly used in preventive and longevity-oriented care, including caloric restriction, weight loss, regular physical activity, hormone replacement therapy, testosterone therapy via aromatization to estrogen, GLP-1–based therapies, and therapeutic plasma exchange. These shifts are associated with movement toward a less pro-inflammatory immune phenotype and parallel improvements in biological age and health outcomes. These findings support the use of IgG glycosylation as a clinically informative biomarker to complement existing risk assessment tools. By enabling earlier identification of individuals at increased biological risk, supporting more personalized intervention strategies, and providing an objective measure of biological response over time, IgG glycosylation may help clinicians move toward more proactive, prevention-focused models of care with the potential to improve long-term healthspan.

Practitioners in age management know that increasing energy, gaining muscle and losing fat are common client goals. Most also know that DEXA scanning is the best way to measure body fat and muscle mass. But many may not know how to interpret and use advanced data in DEXA scans toward the success of their clients and their practices. Through a combination of didactic instruction and case examples, participants will learn (1) how DEXA scanning works, (2) what the most meaningful metrics are, and (3) how to interpret test results and use them to improve diagnosis, treatment and impact.